Camp4, Alnylam partner to identify liver disease targets with machine learning

Camp4 Therapeutics Corp. (Cambridge, Mass.) will deploy its Gene Circuitry Platform under a deal with Alnylam Pharmaceuticals

Read the full 171 word article

User Sign In